Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.41 |
| ▸ | NAALAD2 | Q9Y3Q0 | 5/20 | 0.41 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.41 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4653834 | 1.00 | GAA (0.42) | GAAFOLH1NAALAD2RIMKLATMPRSS15 | |
| SCHEMBL4161725 | 0.89 | GAA (0.41) | GAAFOLH1NAALAD2RIMKLATMPRSS15 | |
| SCHEMBL7902705 | 0.89 | LMNA (0.49) | GAAFOLH1NAALAD2RIMKLATMPRSS15 | |
| SCHEMBL4652770 | 0.89 | GAA (0.41) | GAAFOLH1NAALAD2RIMKLATMPRSS15 | |
| SCHEMBL4469539 | 0.89 | LMNA (0.49) | GAAFOLH1NAALAD2RIMKLATMPRSS15 | |
| SCHEMBL7902128 | 0.89 | GAA (0.41) | GAAFOLH1NAALAD2RIMKLATMPRSS15 | |
| SCHEMBL4652743 | 0.87 | GAA (0.40) | GAAFOLH1NAALAD2RIMKLATMPRSS15 | |
| SCHEMBL4652866 | 0.87 | GAA (0.40) | GAAFOLH1NAALAD2RIMKLATMPRSS15 | |
| SCHEMBL4652731 | 0.83 | CA2 (0.40) | GAAFOLH1NAALAD2RIMKLATMPRSS15 | |
| SCHEMBL4652733 | 0.83 | CA2 (0.40) | GAAFOLH1NAALAD2RIMKLATMPRSS15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355876-B1 | METHODS OF CHEMICAL SYNTHESIS OF PHENOLIC NITROGEN MUSTARD PRODRUGS | CANCER RES INST ROYAL (GB) | 2008-11-05 | — | — | EP | claimed |
| US-6916949-B2 | Methods of chemical systhesis of phenolic nitrogen mustard prodrugs | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-07-12 | — | — | US | claimed |
| US-20040087813-A1 | Methods of chemical systhesis of phenolic nitrogen mustard prodrugs | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2004-05-06 | — | — | US | claimed |
| EP-1355876-A1 | METHODS OF CHEMICAL SYNTHESIS OF PHENOLIC NITROGEN MUSTARD PRODRUGS | Cancer Research Technology Limited (GB) | 2003-10-29 | — | — | EP | claimed |
| WO-2002060862-A1 | METHODS OF CHEMICAL SYNTHESIS OF PHENOLIC NITROGEN MUSTARD PRODRUGS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-08-08 | — | — | WO | claimed |
| EP-1355876-B1 | METHODS OF CHEMICAL SYNTHESIS OF PHENOLIC NITROGEN MUSTARD PRODRUGS | CANCER RES INST ROYAL (GB) | 2008-11-05 | — | — | EP | disclosed |
| US-6916949-B2 | Methods of chemical systhesis of phenolic nitrogen mustard prodrugs | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-07-12 | — | — | US | disclosed |
| US-20040087813-A1 | Methods of chemical systhesis of phenolic nitrogen mustard prodrugs | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2004-05-06 | — | — | US | disclosed |
| EP-1355876-A1 | METHODS OF CHEMICAL SYNTHESIS OF PHENOLIC NITROGEN MUSTARD PRODRUGS | Cancer Research Technology Limited (GB) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002060862-A1 | METHODS OF CHEMICAL SYNTHESIS OF PHENOLIC NITROGEN MUSTARD PRODRUGS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-08-08 | — | — | WO | disclosed |
| US-6277880-B1 | ANTIBODY DIRECTED ENZYME PRODUG THERAPY | ZENECA LIMITED (GB) | 2001-08-21 | — | — | US | disclosed |
| EP-0651740-B1 | AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS | ZENECA LTD (GB) | 1998-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087813-A1 | Methods of chemical systhesis of phenolic nitrogen mustard prodrugs | GGH, GLUL, GSS | GAA 723/4885FOLH1 150/4885NAALAD2 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.